Companies › Vincentage Pharma
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Cardiovascular, Metabolic and endocrine; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CX11 (VCT220) | – | Phase 2 | Hypertension; Obesity & Overweight | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07349381 | CX11 (VCT220) | Phase 1 | Obesity & Overweight | Metabolic and endocrine | Jun 2026 |
| NCT07360275 | CX11 (VCT220) | Phase 2 | Hypertension | Cardiovascular | Dec 2026 |
No annotated target.
–
Sirius Therapeutics Crystalys Therapeutics Lexicon Pharmaceuticals Rare Thyroid Therapeutics International Eddingpharm (Zhuhai)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.